title: Reply from authors re: Camillo Porta, Sergio Bracarda, Romano Danesi. Steroids in prostate cancer: the jury is still out... and even more confused. Eur Urol 2015;67:680-1: Corticosteroids in prostate cancer: known benefits versus potential risks.
authors.affiliation: Royal Marsden Hospital, Sutton, UK. Electronic address: chris.parker@rmh.nhs.uk.
authors.forename: Chris
authors.initials: C
authors.lastname: Parker
authors.affiliation: Institute of Cancer Research, Sutton, UK.
authors.forename: Johann
authors.initials: J
authors.lastname: De Bono
mesh_terms: D003907:Dexamethasone / Q000627:therapeutic use*; D018450:Disease Progression; D006801:Humans; D008297:Male; D011239:Prednisolone / Q000627:therapeutic use*; D017430:Prostate-Specific Antigen / Q000097:blood*; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy*
chemical_list: D003907:Dexamethasone; D011239:Prednisolone; D017430:Prostate-Specific Antigen